These steps typically include separation from the primary tumor, invasion through surrounding tissues
and basement membranes, entry and survival in the circulation, and arrest in a distant target organ. These are usually, but not always, followed by extravasation into the surrounding tissue, survival in the foreign microenvironment, proliferation, and induction of angiogenesis. The treatment against any steps may affect the formation of metastasis. Our results show bevacizumab significantly decreases the ability of invasion and angiogenesis formation in human bone metastatic prostate cancer cells. Conclusions In conclusion, anti-VEGF therapy has an inhibitory effect on human bone metastatic prostate cancer cells. Neutralization of VEGF disturbs the multistep process of metastasis including proliferation, angiogenesis and invasion. Anti-VEGF therapy is a potential adjuvant treatment click here strategy for the treatment of human bone metastatic cancer. References 1. Ossowski L, Aguirre-Ghiso JA: Dormancy of metastatic melanoma. Pigment Cell Melanoma Res 2010, 23:41–65.ATPase inhibitor PubMedCrossRef Repotrectinib ic50 2. Al-Mehdi AB, Tozawa K, Fisher AB, Shientag L, Lee A, Muschel RJ: Intravascular origin of metastasis from the proliferation of endothelium-attached
tumor cells: a new model for metastasis. Nat Med 2000, 6:100–102.PubMedCrossRef 3. Vinothini G, Aravindraja C, Chitrathara K, Nagini S: Correlation of matrix metalloproteinases and their inhibitors Terminal deoxynucleotidyl transferase with hypoxia and angiogenesis in premenopausal patients with adenocarcinoma of the breast. ClinBiochem 2011, 44:969–74. 4. Wang Q, Diao X, Sun J, Chen Z: Regulation of VEGF, MMP-9 and metastasis by CXCR4 in a prostate cancer
cell line. Cell Biology International 2011, 35:897–904.PubMedCrossRef 5. Quaranta M, Daniele A, Coviello M, Venneri MT, Abbate I, Caringella ME, Di Tardo S, Divella R, Trerotoli P, Di Gennaro M, Schittulli F, Fransvea E, Giannelli G: MMP-2, MMP-9, VEGF and CA 15.3 in breast cancer. Anticancer. Res. 2007, 27:3693–600. 6. Bubendorf L, Schopfer A, Wangner U, Sauter G, Moch H, Willi N, Gasser TC, Mihatsch MJ: Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients. Hum. Pathol. 2000, 31:578–583.PubMedCrossRef 7. Ferrer FA, Miller LJ, Andrawis RI, Kurtzman SH, Albertsen PC, Laudone VP, Kreutzer DL: Vascular endothelial growth factor (VEGF) expression in human prostate cancer: in situ and in vitro expression of VEGF by human prostate cancer cells. J. Urol. 1997,157(6):2329–33.PubMedCrossRef 8. Ferrer FA, Miller LJ, Andrawis RI, Kurtzman SH, Albertsen PC, Laudone VP, Kreutzer DL: Angiogenesis and prostate cancer: in vivo and in vitro expression of angiogenesis factors by prostate cancer cells. Urology 1998,51(1):161–7.PubMedCrossRef 9.